DexCom, Inc. logo
DexCom, Inc. (DXCM)
Compare

DXCM Cash Flow Statement

Operating, investing, and financing cash flow analysis

DXCM Quarterly Cash Flow Statement (USD)

Quarterly ReportTTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
09/30/2024
06/30/2024
Cash from Operations (CFO)
1.782B525.600M294.000M659.900M303.000M183.800M301.400M199.500M279.400M
930.400M199.500M267.300M283.800M179.800M105.400M151.700M134.600M143.500M
Depreciation & Amortization
258.900M67.100M65.200M63.600M63.000M60.000M57.800M55.300M52.100M
168.700M43.300M35.000M45.100M45.300M34.200M43.300M43.400M44.700M
Change in Accounts Receivable
4.763B1.089B1.216B1.110B1.349B1.155B1.006B1.002B945.200M
Change in Inventory
Change in Accounts Payable
Change in Working Capital
250.500M147.500M-151.000M231.600M22.400M400K6.400M15.800M67.600M
Cash from Investing
-353.100M-76.600M-101.900M-80.500M-94.100M-87.000M-124.600M-111.200M-66.100M
0.000.000.000.000.000.000.000.000.00
Cash from Financing
Debt Repayment
-535.800M-35.800M-312.800M-187.200M0.000.000.00-750.000M0.00
0.000.000.000.000.000.000.000.000.00
1.429B449.000M192.100M579.400M208.900M96.800M176.800M88.300M213.300M
Net Change in Cash
212.300M199.300M-917.800M676.600M254.200M298.800M-15.100M-316.800M88.000M

DXCM Annual Cash Flow Statement (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Cash from Operations (CFO)
1.441B989.500M748.500M669.500M442.500M475.600M314.500M123.200M
836.300M576.200M541.500M341.200M216.900M493.600M101.100M-127.100M
Depreciation & Amortization
251.800M217.700M186.000M155.900M101.900M67.100M48.700M29.100M
159.600M170.400M150.800M126.500M113.400M119.400M102.700M101.900M
Change in Accounts Receivable
1.216B1.006B973.900M713.300M514.300M428.500M286.300M226.700M
Change in Inventory
Change in Accounts Payable
Change in Working Capital
103.400M108.800M3.200M27.700M-132.000M-20.800M6.100M-40.900M
Cash from Investing
-363.500M-358.800M-236.600M-364.800M-389.200M-199.000M-180.000M-67.100M
0.000.000.00-3.900M-30.200M0.00835.200M-11.300M
Cash from Financing
Debt Repayment
-500.000M-750.000M-688.700M-557.700M0.000.000.00-100.000M
0.000.000.000.000.000.000.000.00
1.077B630.700M511.900M304.700M53.300M276.600M134.500M56.100M
Net Change in Cash
311.800M39.800M-75.800M-410.300M235.400M371.800M-690.700M695.600M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About DexCom, Inc.

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

San Diego, CA
10,200 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Jacob Steven Leach